Core Insights - The 2025 China Biotechnology Innovation Conference opened in Chengdu High-tech Zone, revealing the "2024 China Biopharmaceutical Park Competitiveness Ranking" [1][3] Group 1: Conference Overview - The conference gathered over 1,000 experts and scholars, including 16 academicians from the Chinese Academy of Sciences and the Chinese Academy of Engineering, along with representatives from more than 50 well-known pharmaceutical companies [3] - Topics discussed included AI-enabled innovative drug development, gene and cell therapy, modernization of traditional Chinese medicine, advanced industrial biotechnology, digital healthcare, disruptive technologies and ethical governance, synthetic biology, ophthalmic innovation, and cutting-edge biomedical technologies [3] Group 2: Reports and Rankings - The "2025 China Biopharmaceutical Industry Park Development Status Analysis Report" was released, which systematically compared data from surveyed parks based on five primary competitiveness indicators: environmental, industrial, technological, talent, and cooperation competitiveness [3] - The report evaluated 208 parks, including 112 national high-tech zones, 80 national economic development zones, 15 provincial-level parks, and one other park, ranking them based on 39 secondary indicators such as biopharmaceutical industry output value and R&D investment [3] - Chengdu High-tech Zone, along with Zhongguancun National Independent Innovation Demonstration Zone, Suzhou Industrial Park, and Shanghai Zhangjiang Hi-Tech Park, ranked in the top tier of comprehensive competitiveness [3] Group 3: New Initiatives - The "Global New Drug Discovery Center" was officially inaugurated during the conference, which will leverage 22 leading global drug discovery databases and integrate resources from over 3,000 biopharmaceutical companies to create a comprehensive service system covering target discovery, compound screening, drugability assessment, business development transaction facilitation, and project management [4]